Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Deals

Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round

Fineline Cube Jul 3, 2023

Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised...

Company Drug

Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China

Fineline Cube Jul 3, 2023

Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...

Company Drug

SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment

Fineline Cube Jul 3, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis

Fineline Cube Jul 3, 2023

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...

Company Drug

InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection

Fineline Cube Jul 3, 2023

InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...

Company Drug

Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer

Fineline Cube Jul 3, 2023

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study

Fineline Cube Jul 3, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China

Fineline Cube Jul 3, 2023

The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a...

Company Drug

Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis

Fineline Cube Jul 3, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...

Company Medical Device

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Fineline Cube Jul 3, 2023

China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...

Company Deals

Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence

Fineline Cube Jul 3, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Deals

Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1

Fineline Cube Jul 3, 2023

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...

Company Drug

ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study

Fineline Cube Jul 3, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...

Company Drug

Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment

Fineline Cube Jul 3, 2023

The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...

Company Drug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...

Company Deals

Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development

Fineline Cube Jun 30, 2023

Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...

Company Drug

Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 30, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update

Fineline Cube Jun 30, 2023

The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...

Company Drug

Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection

Fineline Cube Jun 30, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Posts pagination

1 … 515 516 517 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.